• Je něco špatně v tomto záznamu ?

A randomised, placebo-controlled, phase III trial of leniolisib in activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS): Adolescent and adult subgroup analysis

VK. Rao, A. Šedivá, VASH. Dalm, A. Plebani, C. Schuetz, A. Shcherbina, A. Trizzino, Y. Zharankova, A. Orpia, E. Kulm, S. Webster, J. Körholz, V. Lougaris, Y. Rodina, N. Conlon, T. Coulter, J. Bradt, A. Relan, G. Uzel

. 2025 ; 270 (-) : 110400. [pub] 20241117

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, klinické zkoušky, fáze III, randomizované kontrolované studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc25002873

Grantová podpora
Z99 AI999999 Intramural NIH HHS - United States
ZIA AI000732 Intramural NIH HHS - United States

Activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) is an ultra-rare, progressive genetic disease, characterised by immune deficiency and dysregulation, affecting individuals from birth. In a 12-week phase III randomised placebo-controlled trial, leniolisib, a selective PI3Kδ inhibitor, was well-tolerated and met both co-primary endpoints (change from Baseline in log10-transformed sum of product of diameters of index lymph nodes and percentage of naïve/total B cells at Day 85). Here, prespecified subgroup analyses are reported in adolescents aged 12-17 years (leniolisib, n = 8; placebo, n = 4) and adults aged ≥18 (leniolisib, n = 13; placebo, n = 6). In both subgroups, leniolisib reduced lymphadenopathy (least squares mean change versus placebo: adolescents, -0.4 versus -0.1; adults, -0.3 versus 0.1) and increased the percentage of naïve B cells (least squares mean change: adolescents, 44.5 versus -16.5; adults, 28.4 versus -1.1). Leniolisib was well-tolerated in both adolescents and adults. These results show leniolisib is an effective APDS treatment in both subpopulations. PLAIN LANGUAGE SUMMARY: What is activated PI3Kδ syndrome (APDS)? APDS is an ultra-rare disease in which the immune system does not work correctly. People with APDS have a wide range of symptoms, including infections, certain organs associated with the immune system becoming larger, and worse quality of life. These symptoms generally start in childhood. Why was this study carried out? Current treatments only treat the symptoms of APDS, rather than correcting the cause of the problem. These treatments can also have significant side effects. A new medication for APDS called leniolisib aims to treat the underlying cause of the disease. This publication reports results from a clinical trial of leniolisib which compared patients who received leniolisib with patients who received a placebo. The aim of this report was to examine these clinical trial results to understand if leniolisib is effective and safe when treating both adolescents (12-17 years old) and adults (18 years and older) with APDS. What were the results of this study? Leniolisib improved the number of certain immune cells, compared to patients who did not receive leniolisib, in both adolescents and adults with APDS. Leniolisib also reduced the size of the enlarged immune system organs in both adolescents and adults with APDS. There were no major safety concerns for either age group who received leniolisib. What do these results mean? These results show that leniolisib can help the immune system to work in a way that is closer to those without APDS. This new treatment is effective and generally well-tolerated for both adolescents and adults. These results indicate that people with APDS are able to start treatment with leniolisib during adolescence, which may slow the build-up of symptoms and may also have a positive impact on the quality of their lives.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25002873
003      
CZ-PrNML
005      
20250206103923.0
007      
ta
008      
250121e20241117xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.clim.2024.110400 $2 doi
035    __
$a (PubMed)39561927
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Rao, V Koneti $u National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States. Electronic address: korao@niaid.nih.gov
245    12
$a A randomised, placebo-controlled, phase III trial of leniolisib in activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS): Adolescent and adult subgroup analysis / $c VK. Rao, A. Šedivá, VASH. Dalm, A. Plebani, C. Schuetz, A. Shcherbina, A. Trizzino, Y. Zharankova, A. Orpia, E. Kulm, S. Webster, J. Körholz, V. Lougaris, Y. Rodina, N. Conlon, T. Coulter, J. Bradt, A. Relan, G. Uzel
520    9_
$a Activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) is an ultra-rare, progressive genetic disease, characterised by immune deficiency and dysregulation, affecting individuals from birth. In a 12-week phase III randomised placebo-controlled trial, leniolisib, a selective PI3Kδ inhibitor, was well-tolerated and met both co-primary endpoints (change from Baseline in log10-transformed sum of product of diameters of index lymph nodes and percentage of naïve/total B cells at Day 85). Here, prespecified subgroup analyses are reported in adolescents aged 12-17 years (leniolisib, n = 8; placebo, n = 4) and adults aged ≥18 (leniolisib, n = 13; placebo, n = 6). In both subgroups, leniolisib reduced lymphadenopathy (least squares mean change versus placebo: adolescents, -0.4 versus -0.1; adults, -0.3 versus 0.1) and increased the percentage of naïve B cells (least squares mean change: adolescents, 44.5 versus -16.5; adults, 28.4 versus -1.1). Leniolisib was well-tolerated in both adolescents and adults. These results show leniolisib is an effective APDS treatment in both subpopulations. PLAIN LANGUAGE SUMMARY: What is activated PI3Kδ syndrome (APDS)? APDS is an ultra-rare disease in which the immune system does not work correctly. People with APDS have a wide range of symptoms, including infections, certain organs associated with the immune system becoming larger, and worse quality of life. These symptoms generally start in childhood. Why was this study carried out? Current treatments only treat the symptoms of APDS, rather than correcting the cause of the problem. These treatments can also have significant side effects. A new medication for APDS called leniolisib aims to treat the underlying cause of the disease. This publication reports results from a clinical trial of leniolisib which compared patients who received leniolisib with patients who received a placebo. The aim of this report was to examine these clinical trial results to understand if leniolisib is effective and safe when treating both adolescents (12-17 years old) and adults (18 years and older) with APDS. What were the results of this study? Leniolisib improved the number of certain immune cells, compared to patients who did not receive leniolisib, in both adolescents and adults with APDS. Leniolisib also reduced the size of the enlarged immune system organs in both adolescents and adults with APDS. There were no major safety concerns for either age group who received leniolisib. What do these results mean? These results show that leniolisib can help the immune system to work in a way that is closer to those without APDS. This new treatment is effective and generally well-tolerated for both adolescents and adults. These results indicate that people with APDS are able to start treatment with leniolisib during adolescence, which may slow the build-up of symptoms and may also have a positive impact on the quality of their lives.
650    _2
$a lidé $7 D006801
650    _2
$a mladiství $7 D000293
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a dítě $7 D002648
650    12
$a primární imunodeficience $x farmakoterapie $x genetika $7 D000081207
650    _2
$a dospělí $7 D000328
650    12
$a fosfatidylinositol-3-kinasy třídy I $x genetika $x antagonisté a inhibitory $7 D058534
650    _2
$a mladý dospělý $7 D055815
650    _2
$a B-lymfocyty $x imunologie $x účinky léků $7 D001402
650    _2
$a lidé středního věku $7 D008875
650    _2
$a dvojitá slepá metoda $7 D004311
655    _2
$a časopisecké články $7 D016428
655    _2
$a klinické zkoušky, fáze III $7 D017428
655    _2
$a randomizované kontrolované studie $7 D016449
700    1_
$a Šedivá, Anna $u Department of Immunology, Motol University Hospital, 2nd Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Dalm, Virgil A S H $u Department of Internal Medicine, Division of Allergy and Clinical Immunology; Department of Immunology, Erasmus University Medical Center, Rotterdam, the Netherlands
700    1_
$a Plebani, Alessandro $u Pediatrics Clinic, Department of Clinical and Experimental Sciences, University of Brescia, Azienda Socio Sanitaria Territoriale Spedali Civili di Brescia, Brescia, Italy
700    1_
$a Schuetz, Catharina $u Pediatric Immunology, Department of Pediatrics, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
700    1_
$a Shcherbina, Anna $u Department of Immunology, Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia
700    1_
$a Trizzino, Antonino $u Department of Pediatric Hematology and Oncology, ARNAS Ospedali Civico Di Cristina Benfratelli Hospital, Palermo, Italy
700    1_
$a Zharankova, Yulia $u Belarusian Research Center for Pediatric Oncology, Hematology and Immunology, Minsk, Belarus
700    1_
$a Orpia, Alanvin $u National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States
700    1_
$a Kulm, Elaine $u Clinical Research Directorate, Frederick National Laboratory for Cancer Research, Bethesda, MD, United States
700    1_
$a Webster, Sharon $u National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States
700    1_
$a Körholz, Julia $u Pediatric Immunology, Department of Pediatrics, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
700    1_
$a Lougaris, Vassilios $u Pediatrics Clinic, Department of Clinical and Experimental Sciences, University of Brescia, Azienda Socio Sanitaria Territoriale Spedali Civili di Brescia, Brescia, Italy
700    1_
$a Rodina, Yulia $u Department of Immunology, Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia
700    1_
$a Conlon, Niall $u Wellcome Trust Clinical Research Facility, St. James's Hospital and School of Medicine, Trinity College Dublin, Ireland
700    1_
$a Coulter, Tanya $u Regional Immunology Services of Northern Ireland, Belfast Health and Social Care Trust, United Kingdom
700    1_
$a Bradt, Jason $u Pharming Healthcare Inc, Warren, NJ, United States
700    1_
$a Relan, Anurag $u Pharming Healthcare Inc, Warren, NJ, United States
700    1_
$a Uzel, Gulbu $u National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States
773    0_
$w MED00005218 $t Clinical immunology $x 1521-7035 $g Roč. 270 (20241117), s. 110400
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39561927 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250121 $b ABA008
991    __
$a 20250206103918 $b ABA008
999    __
$a ok $b bmc $g 2262960 $s 1238880
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 270 $c - $d 110400 $e 20241117 $i 1521-7035 $m Clinical immunology $n Clin Immunol $x MED00005218
GRA    __
$a Z99 AI999999 $p Intramural NIH HHS $2 United States
GRA    __
$a ZIA AI000732 $p Intramural NIH HHS $2 United States
LZP    __
$a Pubmed-20250121

Najít záznam

Citační ukazatele

Možnosti archivace